Nothing Special   »   [go: up one dir, main page]

DE69435108D1 - Defekte adenovirus-vektoren und deren verwendung in der gentherapie - Google Patents

Defekte adenovirus-vektoren und deren verwendung in der gentherapie

Info

Publication number
DE69435108D1
DE69435108D1 DE69435108T DE69435108T DE69435108D1 DE 69435108 D1 DE69435108 D1 DE 69435108D1 DE 69435108 T DE69435108 T DE 69435108T DE 69435108 T DE69435108 T DE 69435108T DE 69435108 D1 DE69435108 D1 DE 69435108D1
Authority
DE
Germany
Prior art keywords
gene therapy
adenovirus vectors
defective adenovirus
defective
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69435108T
Other languages
English (en)
Inventor
Michel Perricaudet
Emmanuelle Vigne
Patrice Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centelion SAS
Original Assignee
Centelion SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9308596A external-priority patent/FR2707664B1/fr
Priority claimed from FR9404590A external-priority patent/FR2718749B1/fr
Application filed by Centelion SAS filed Critical Centelion SAS
Application granted granted Critical
Publication of DE69435108D1 publication Critical patent/DE69435108D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69435108T 1993-07-13 1994-07-08 Defekte adenovirus-vektoren und deren verwendung in der gentherapie Expired - Fee Related DE69435108D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9308596A FR2707664B1 (fr) 1993-07-13 1993-07-13 Vecteurs viraux et utilisation en thérapie génique.
FR9404590A FR2718749B1 (fr) 1994-04-18 1994-04-18 Vecteurs viraux et utilisation en thérapie génique.
PCT/FR1994/000851 WO1995002697A1 (fr) 1993-07-13 1994-07-08 Vecteurs adenoviraux defectifs et utilisation en therapie genique

Publications (1)

Publication Number Publication Date
DE69435108D1 true DE69435108D1 (de) 2008-08-14

Family

ID=26230472

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69435108T Expired - Fee Related DE69435108D1 (de) 1993-07-13 1994-07-08 Defekte adenovirus-vektoren und deren verwendung in der gentherapie

Country Status (23)

Country Link
US (1) US20030096787A1 (de)
EP (1) EP0667912B1 (de)
JP (1) JP4190028B2 (de)
KR (1) KR100356615B1 (de)
CN (1) CN1115414C (de)
AT (1) ATE399873T1 (de)
AU (1) AU7264694A (de)
BR (1) BR9405507A (de)
CA (1) CA2144040A1 (de)
CZ (1) CZ287157B6 (de)
DE (1) DE69435108D1 (de)
DK (1) DK0667912T3 (de)
ES (1) ES2310924T3 (de)
FI (1) FI951138A (de)
HU (1) HU216871B (de)
IL (1) IL110284A0 (de)
NO (1) NO321309B1 (de)
NZ (1) NZ269156A (de)
PL (1) PL179877B1 (de)
PT (1) PT667912E (de)
RU (1) RU2219241C2 (de)
SK (1) SK282843B6 (de)
WO (1) WO1995002697A1 (de)

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
WO1992015680A1 (en) 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
CA2162497A1 (en) 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
JP3816518B2 (ja) * 1994-06-10 2006-08-30 ジェンベク、インコーポレイティッド 相補的なアデノウイルスベクター系と細胞系
DE69531387T2 (de) * 1994-08-16 2004-04-22 Crucell Holland B.V. Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
CA2203809C (en) * 1994-10-28 2008-06-03 James M. Wilson Recombinant adenovirus and methods of use thereof
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
FR2727867B1 (fr) * 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2738575B1 (fr) * 1995-09-08 1997-10-10 Centre Nat Rech Scient Cellules pour la production d'adenovirus recombinants
FR2741891B1 (fr) * 1995-06-01 1998-01-09 Centre Nat Rech Scient Cellules pour la production d'adenovirus recombinants
FR2729674B1 (fr) * 1995-01-20 1997-04-11 Centre Nat Rech Scient Cellules pour la production d'adenovirus recombinants
FR2730504B1 (fr) * 1995-02-13 1997-03-28 Rhone Poulenc Rorer Sa Procede de preparation de genomes d'adenovirus recombinants
US5637456A (en) * 1995-02-17 1997-06-10 The University Of Texas, Board Of Regents Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
EA001616B1 (ru) 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US20020103147A1 (en) 1997-09-05 2002-08-01 Hammond H. Kirk Gene therapy for congestive heart failure
FR2731710B1 (fr) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
JP3770333B2 (ja) * 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
FR2732357B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
EP0821739B1 (de) * 1995-04-17 2003-06-18 The Board Of Regents, The University Of Texas System Adenovirus helfervirus system
FR2734826B1 (fr) * 1995-06-01 1997-07-04 Rhone Poulenc Rorer Sa Deltap62, ses variants, sequences nucleiques et leurs utilisations
US6019978A (en) * 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
US5698202A (en) * 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1997000954A1 (en) * 1995-06-23 1997-01-09 Board Of Regents, The University Of Texas System C-cam expression constructs and their application in cancer therapy
FR2735789B1 (fr) 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
FR2737222B1 (fr) * 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
FR2737221B1 (fr) * 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux pour la therapie genique
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
US6482803B1 (en) 1995-09-01 2002-11-19 Board Of Regents, The University Of Texas System Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A
AU7674896A (en) * 1995-10-31 1997-05-22 Board Of Regents, The University Of Texas System Adenovirus-antisense k-ras expression vectors and their application in cancer therapy
US6004797A (en) * 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
JP2006075171A (ja) * 1995-11-09 2006-03-23 Avigen Inc 組換えａａｖビリオン産生における使用のための補助機能
JP2000500017A (ja) * 1995-11-17 2000-01-11 ウォルフガンク−エム フランツ 遺伝子治療核酸構造体、その製造と心臓疾患治療へのその利用
FR2746110B1 (fr) * 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
US6132989A (en) * 1996-06-03 2000-10-17 University Of Washington Methods and compositions for enhanced stability of non-adenoviral DNA
US20040156861A1 (en) 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US6083716A (en) * 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
CA2266342C (en) * 1996-09-25 2010-06-08 Novartis Ag Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
BR9713847A (pt) 1996-12-06 2000-02-29 Rhone Poulenc Rorer Pharma Polipeptìdeo isolado codificado por um gene semelhante a lipase, composição, composição farmacêutica, fragmento antigênico, ácido nucleico isolado, vetor, célula recombinante, anticorpo, célula de hibridoma, processos para preparar um polipeptìdeo, para triar agonistas ou antagonistas de atividade llg, para a hidrólise enzimática de um éster de fosfatidilcolina, e para melhorar o perfil de lipìdeo no soro de um humano ou outro animal tendo um perfil de lipìdeo indesejável, e, camundongo transgênico.
WO1998032860A1 (en) * 1997-01-28 1998-07-30 Baxter International Inc. Methods for highly efficient generation of adenoviral vectors
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
EP0979290A2 (de) 1997-04-28 2000-02-16 Aventis Pharma S.A. Adenoviren - vermittelte intratumorale verabreichung eines angiogenese - antagonists zur behandlung der tumoren
AUPO856097A0 (en) * 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
US6653088B1 (en) 1997-10-24 2003-11-25 Aventis Pharma S.A. Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
ATE302267T1 (de) 1998-01-08 2005-09-15 Aventis Pharma Inc Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
ES2333071T5 (es) 1998-01-14 2015-08-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos de Neisseria meningitidis
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
BR9910089A (pt) 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
US6506889B1 (en) 1998-05-19 2003-01-14 University Technology Corporation Ras suppressor SUR-8 and related compositions and methods
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US6328958B1 (en) * 1998-08-28 2001-12-11 Duke University Deleted adenovirus vectors and methods of making and administering the same
US6441156B1 (en) 1998-12-30 2002-08-27 The United States Of America As Represented By The Department Of Health And Human Services Calcium channel compositions and methods of use thereof
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6291226B1 (en) * 1999-02-25 2001-09-18 National Research Council Of Canada Adenovirus mutants with deleted protease gene
PT1533380E (pt) * 1999-04-15 2010-02-09 Crucell Holland Bv Produção de proteínas recombinantes numa célula humana compreendendo pelo menos uma proteína e1 de adenovírus
BR0010130A (pt) 1999-04-30 2002-06-04 Chiron Spa Antìgenos de neisseria conservados
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
FR2794771B1 (fr) 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
ES2507100T3 (es) 2000-01-17 2014-10-14 Novartis Vaccines And Diagnostics S.R.L. Vacuna OMV suplementada contra meningococo
WO2001074900A2 (en) 2000-03-31 2001-10-11 Aventis Pharmaceuticals Products Inc. Nuclear factor kb inducing factor
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
WO2001092550A2 (en) * 2000-05-31 2001-12-06 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
EP1328543B1 (de) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nukleinsäuren und proteine von gruppen a und b-streptokokken
US7060442B2 (en) 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
BR0116756A (pt) 2000-12-28 2005-01-04 Wyeth Corp Proteìna protetora recombinante de streptococcus pneumoniae e uso da mesma
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AUPR518501A0 (en) 2001-05-22 2001-06-14 Unisearch Limited Yin yang-1
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
US7569217B2 (en) 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
ATE406912T1 (de) 2001-12-12 2008-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
EP1465664A1 (de) * 2002-01-18 2004-10-13 Schering Aktiengesellschaft Stabilisierte formulierungen von adenovirus
US7319001B2 (en) 2002-03-09 2008-01-15 Neurogenex Co., Ltd. High throughput system for producing recombinant viruses using site-specific recombination
EP2316921B1 (de) 2002-05-24 2014-05-14 Merck Sharp & Dohme Corp. Humaner neutraliserender Anti-IGFR Antikörper
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
RU2244928C2 (ru) * 2003-02-19 2005-01-20 Пинигина Нина Максимовна Эндогенная фармацевтическая композиция, полученная на основе целенаправленной активации гуморальных медиаторов нервных окончаний коры головного мозга
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2005012537A2 (en) * 2003-07-25 2005-02-10 Genvec, Inc. Adenoviral vector-based vaccines
DE602004025726D1 (de) 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
US7432057B2 (en) 2004-01-30 2008-10-07 Michigan State University Genetic test for PSE-susceptible turkeys
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
CA2563396A1 (en) 2004-04-12 2005-11-24 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method of using adenoviral vectors to induce an immune response
BRPI0510475B8 (pt) 2004-05-26 2021-05-25 Bayer Pharma AG adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
JP5022217B2 (ja) 2004-06-18 2012-09-12 デューク ユニバーシティー 匂い物質受容体のモジュレーター
US7604798B2 (en) 2004-07-15 2009-10-20 Northwestern University Methods and compositions for importing nucleic acids into cell nuclei
AU2005274948B2 (en) 2004-07-16 2011-09-22 Genvec, Inc. Vaccines against aids comprising CMV/R-nucleic acid constructs
JP2008511336A (ja) * 2004-09-01 2008-04-17 アメリカ合衆国 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
EP2002003B1 (de) 2005-05-27 2015-12-30 Ospedale San Raffaele S.r.l. Vektor welcher mi-rna enthält
EP1929021A2 (de) 2005-08-31 2008-06-11 Genvec, Inc. Malariaimpfstoffe auf adenovirusvektorbasis
EP1951297A2 (de) 2005-11-10 2008-08-06 GenVec, Inc. Adenoviraler vektorbasierter impfstoff für die maul- und klauen-seuche
EP2054431B1 (de) 2006-06-09 2011-08-31 Novartis AG Bakterielle adhäsine konformere
MY151438A (en) 2006-07-28 2014-05-30 Sanofi Aventis Compositions and method for treatment of tumors
EP2068922B1 (de) 2006-10-19 2012-06-27 CSL Limited Anti-il-13r-alpha-1-antikörper und ihre verwendung
EP2829551B1 (de) 2006-10-19 2017-12-13 CSL Limited Hochaffine Antikörperantagonisten des Interleukin-13-Rezeptors Alpha 1
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
KR20090128494A (ko) 2007-03-24 2009-12-15 겐자임 코포레이션 인간 아포리포프로틴 ｂ에 상보적인 안티센스 올리고뉴클레오타이드 투여
CN101067139B (zh) * 2007-05-14 2010-05-26 清华大学深圳研究生院 一种RNAi载体及其应用
CN101619324B (zh) * 2008-07-01 2013-06-26 中国疾病预防控制中心病毒病预防控制所 复制缺陷型重组腺病毒Ad41载体系统及其应用
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
JP2012508174A (ja) 2008-11-05 2012-04-05 ワイス・エルエルシー β溶血性連鎖球菌（ＢＨＳ）疾患を予防するための多成分免疫原性組成物
EP2373338B1 (de) 2008-12-03 2017-02-15 The Johns Hopkins University Annexin a2 als immunologisches zielmolekül
KR20110091796A (ko) 2008-12-04 2011-08-12 오피케이오 큐알엔에이, 엘엘씨 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
BR112012010824A2 (pt) 2009-11-09 2018-03-06 Genvec Inc adenovirus simios e métodos de uso
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
EP2547362B1 (de) 2010-03-17 2021-08-25 Cornell University Unterbrochener impfstoff auf adenovirusbasis gegen drogenmissbrauch
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
PL3246044T5 (pl) 2010-08-23 2024-06-17 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
ES2728282T3 (es) 2010-09-10 2019-10-23 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
EP2654786B1 (de) 2010-12-20 2019-02-20 GenVec, Inc. Auf adenovirusvektor basierender impfstoff gegen denguefieber
AU2012236345B2 (en) 2011-03-29 2014-10-02 Dynavax Technologies Corporation TLR8 transgenic animals
CN102240405A (zh) * 2011-05-09 2011-11-16 上海市第十人民医院 ApoA-Ⅰmilano基因药物
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
CA2851251C (en) 2011-10-05 2023-09-12 Genvec, Inc. Simian (gorilla) adenovirus or adenoviral vectors and methods of use
US9580476B2 (en) 2011-10-05 2017-02-28 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (RSV) vaccine
BR112014008249B1 (pt) 2011-10-05 2022-03-15 Genvec Inc Adenovírus ou vetor adenoviral e composição com os mesmos
EP2764012B1 (de) 2011-10-05 2022-02-23 GenVec, Inc. Adenovirusvektoren und verwendungsverfahren dafür
CA3132111A1 (en) 2011-12-28 2013-07-04 Nippon Shinyaku Co., Ltd. Antisense nucleic acids for skipping of exon 55 of human dystrophin gene
US20150157700A1 (en) 2012-02-02 2015-06-11 GanVec, Inc. Adenoviral vector-based malaria vaccine
RU2491097C1 (ru) * 2012-02-16 2013-08-27 Общество с ограниченной ответственностью "НТфарма" Фармацевтическая композиция и способ терапии нейродегенеративных заболеваний, в частности бокового амиотрофического склероза
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2855511B1 (de) 2012-05-29 2019-07-24 GenVec, Inc. Impfstoff gegen das herpes-simplex virus
WO2013181128A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Modified serotype 28 adenoviral vectors
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
US10981961B2 (en) 2013-03-11 2021-04-20 University Of Florida Research Foundation, Incorporated Delivery of card protein as therapy for occular inflammation
DK2970398T3 (da) 2013-03-13 2024-08-05 Us Health Præfusions-rsv-f-proteiner og anvendelse deraf
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
RU2710307C2 (ru) * 2013-09-12 2019-12-26 Байомарин Фармасьютикал Инк. Векторы экспрессии фактора viii на основе аденоассоциированного вируса
CA3183645A1 (en) 2013-10-25 2015-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
WO2015127094A1 (en) 2014-02-19 2015-08-27 University Of Florida Research Foundation, Inc. Delivery of nrf2 as therapy for protection against reactive oxygen species
EP3189067B1 (de) 2014-09-04 2021-05-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Rekombinante hiv-1 hüllproteine und deren verwendung
EP3236998A1 (de) 2014-12-24 2017-11-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Rekombinante metapneumovirusproteine und deren verwendung
CN107406835A (zh) 2015-01-20 2017-11-28 美利坚合众国,由健康及人类服务部部长代表 表达嵌合rsv/bpiv3f蛋白的重组人/牛副流感病毒3(b/hpiv3)及其用途
CN107427666B (zh) 2015-01-30 2022-11-04 加利福尼亚大学校董 脊髓软膜下基因递送系统
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
ES2780366T3 (es) 2015-04-30 2020-08-25 Psioxus Therapeutics Ltd Adenovirus oncolítico que codifica una proteína b7
EP3307894A4 (de) * 2015-06-10 2019-01-16 American Gene Technologies International, Inc. System und verfahren zur nichtintegralen viralen ausgabe und verfahren zur verwendung davon
WO2017007994A1 (en) 2015-07-08 2017-01-12 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
CN108289909A (zh) 2015-10-19 2018-07-17 巴尔的摩马里兰大学 用于产生工程改造的人原代血液树突细胞系的方法
EA201891021A1 (ru) 2015-12-17 2018-11-30 Псайоксус Терапьютикс Лимитед Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
AU2017207906B2 (en) 2016-01-15 2021-03-11 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
WO2017139392A1 (en) 2016-02-08 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant hiv-1 envelope proteins and their use
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
EP3426291A1 (de) 2016-03-09 2019-01-16 The U.S.A. as represented by the Secretary, Department of Health and Human Services Rekombinante hiv-1-hüllproteine und deren verwendung
EP3426777B1 (de) 2016-03-09 2022-02-16 American Gene Technologies International Inc. Kombinationsvektoren und verfahren zur behandlung von krebs
US11472859B2 (en) 2016-03-28 2022-10-18 The Regents Of The University Of California Method and composition for treating neuronal hyper-excitabtiity
US11560412B2 (en) 2016-04-01 2023-01-24 University Of Maryland, Baltimore Compositions comprising GRIM-19 therapeutics and methods of use
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
CA2971303A1 (en) * 2016-06-21 2017-12-21 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
JP6971492B2 (ja) 2016-07-08 2021-11-24 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖ予備免疫化および免疫療法
US11583562B2 (en) 2016-07-21 2023-02-21 American Gene Technologies International Inc. Viral vectors for treating Parkinson's disease
JP2019532621A (ja) 2016-08-29 2019-11-14 サイオクサス セラピューティクス リミテッド 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
TWI817933B (zh) 2016-09-20 2023-10-11 德商百靈佳殷格翰維美迪加股份有限公司 新穎ehv插入位點orf70
EA201990717A1 (ru) 2016-09-20 2019-10-31 Новая вакцина против гриппа свиней
CA3036293A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New promoters
CN109715219B (zh) 2016-09-20 2024-03-01 勃林格殷格翰动物保健有限公司 犬腺病毒载体
US11155832B2 (en) 2016-09-30 2021-10-26 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into T cells
EP3518968B1 (de) 2016-10-03 2022-01-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1-env-fusionspeptid-immunogene und deren verwendung
WO2018081318A1 (en) 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
US11147249B2 (en) 2016-12-08 2021-10-19 Alector Llc Siglec transgenic mice and methods of use thereof
CA3043790A1 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
US11235056B2 (en) 2017-03-24 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of HIV-1 gp120 and their use
EP3607072A4 (de) 2017-04-03 2021-01-06 American Gene Technologies International Inc. Zusammensetzungen und verfahren zur behandlung von phenylketonurie
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
EP4124658A3 (de) 2017-10-16 2023-04-19 Voyager Therapeutics, Inc. Behandlung von amyotropher lateralsklerose (als)
US11136356B2 (en) 2017-10-16 2021-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
AU2018359420A1 (en) 2017-10-31 2020-06-04 Kalivir Immunotherapeutics, Inc. Platform oncolytic vector for systemic delivery
US11470827B2 (en) 2017-12-12 2022-10-18 Alector Llc Transgenic mice expressing human TREM proteins and methods of use thereof
WO2019173463A1 (en) 2018-03-06 2019-09-12 Intrexon Corporation Hepatitis b vaccines and uses of the same
US20210361318A1 (en) 2018-07-02 2021-11-25 Voyager Therapeutics, Inc. Cannula system and use thereof
US20210254103A1 (en) 2018-07-02 2021-08-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
CA3117390A1 (en) 2018-10-22 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant gp120 protein with v1-loop deletion
CN114761546A (zh) 2019-10-08 2022-07-15 波士顿学院董事会 含有多个不同非天然氨基酸的蛋白质以及制备和使用此类蛋白质的方法
CN110714027A (zh) * 2019-10-28 2020-01-21 嘉铭(固安)生物科技有限公司 一种表达质粒、用于包装二代腺病毒的细胞株及其应用
AU2021221127A1 (en) 2020-02-11 2022-09-22 Board Of Regents, The University Of Texas System SARS-CoV-2 vaccine
US11213482B1 (en) 2020-03-05 2022-01-04 University of Pittsburgh—Of the Commonwealth System of Higher Educat SARS-CoV-2 subunit vaccine and microneedle array delivery system
EP4114449A2 (de) 2020-03-05 2023-01-11 Neotx Therapeutics Ltd. Verfahren und zusammensetzungen zur behandlung von krebs mit immunzellen
US11773391B2 (en) 2020-04-01 2023-10-03 University of Pittsburgh—of the Commonwealth System of Higher Education Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
EP4142785A2 (de) 2020-04-29 2023-03-08 The United States of America, as represented by the Secretary, Department of Health and Human Services Rekombinante menschliche metapneumovirus f proteine und deren verwendung
WO2021247995A2 (en) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions and methods of treating neuropathic pain
WO2022035860A2 (en) 2020-08-10 2022-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Replication-competent adenovirus type 4-hiv env vaccines and their use
US20240228549A1 (en) 2021-04-29 2024-07-11 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Prefusion-stabilized lassa virus glycoprotein complex and its use
CN117241813A (zh) 2021-04-30 2023-12-15 卡利威尔免疫治疗公司 用于修饰的mhc表达的溶瘤病毒
CA3217862A1 (en) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Animal model having homologous recombination of mouse pth1 receptor
US20240277829A1 (en) 2021-08-03 2024-08-22 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
AU2022371414A1 (en) 2021-10-20 2024-05-02 University Of Copenhagen Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss
EP4426331A1 (de) 2021-11-02 2024-09-11 University of Rochester Tcf7l2-vermittelte remyelinisierung im gehirn
WO2023091696A1 (en) 2021-11-19 2023-05-25 Christiana Care Gene Editing Institute, Inc. Adenovirus delivery system for cancer treatment
WO2023192835A1 (en) 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Base-covered hiv-1 envelope ectodomains and their use
WO2023196898A1 (en) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
WO2024163747A2 (en) 2023-02-02 2024-08-08 University Of Rochester Competitive replacement of glial cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
CA2145641C (en) * 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.

Also Published As

Publication number Publication date
JP4190028B2 (ja) 2008-12-03
EP0667912A1 (de) 1995-08-23
EP0667912B1 (de) 2008-07-02
NO950939D0 (no) 1995-03-10
KR100356615B1 (ko) 2003-04-03
CZ287157B6 (en) 2000-10-11
FI951138A0 (fi) 1995-03-10
JPH08501703A (ja) 1996-02-27
FI951138A (fi) 1995-04-13
NO950939L (no) 1995-03-10
CA2144040A1 (fr) 1995-01-26
RU2219241C2 (ru) 2003-12-20
US20030096787A1 (en) 2003-05-22
HU216871B (hu) 1999-09-28
KR950703649A (ko) 1995-09-20
SK31295A3 (en) 1996-05-08
WO1995002697A1 (fr) 1995-01-26
CN1115414C (zh) 2003-07-23
HU9500732D0 (en) 1995-04-28
ATE399873T1 (de) 2008-07-15
CN1113390A (zh) 1995-12-13
ES2310924T3 (es) 2009-01-16
PT667912E (pt) 2008-10-15
CZ63995A3 (en) 1995-11-15
NO321309B1 (no) 2006-04-24
NZ269156A (en) 1996-03-26
DK0667912T3 (da) 2008-11-10
SK282843B6 (sk) 2002-12-03
RU95108217A (ru) 1997-06-10
BR9405507A (pt) 1999-05-25
AU7264694A (en) 1995-02-13
PL308122A1 (en) 1995-07-24
PL179877B1 (pl) 2000-11-30
IL110284A0 (en) 1994-10-21
HUT72558A (en) 1996-05-28

Similar Documents

Publication Publication Date Title
ATE399873T1 (de) Defekte adenovirus-vektoren und deren verwendung in der gentherapie
MX9603002A (es) Procedimiento para la preparacion de virus asociados a los adenovirus (aav), recombinantes, y usos de los mismos.
DE3586423D1 (de) Hitzehaertbare siliconharze, deren verwendung und stabilisator dafuer.
FR2712603B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
GR930300079T1 (en) Benzoic acid substituted derivatives having cardiovascular activity.
BR9607583B1 (pt) plasmìdios procarióticos recombinantes.
NO910982D0 (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
FR2712602B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
NO971247D0 (no) Defektive, rekombinante adenoviruser med inaktivt IVa2-gen
DE3766441D1 (de) Anilinotriazine und deren verwendung.
DK0745122T3 (da) Galninreceptor, nukleinsyrer, transformerede celler og anvendelser heraf
NO950420D0 (no) Interferon endelse derav
NO902248D0 (no) Renininhiberende peptider, deres fremstilling og anvendelse i legemidler.
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
FI971377A0 (fi) Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni
DE3868608D1 (de) Organozinn-alkoxycarbonylphenylmercaptide und deren verwendung.
FI940822A (fi) Foerfarande foer mikrobiologisk rening av material, som innehaoller skadliga aemnen
NO910331D0 (no) Rekombinant plasmid, fremgangsmaate til dets fremstilling og anvendelse av plasmidet i produksjonen av proteiner.
ITRM920232A0 (it) Procedimento per la preparazione di acilfosfatasi mediante cellule geneticamente modificate, e vettori ricombinanti ed organismi modificati ottenibili nel procedimento.
NO924063D0 (no) Nye i etylendelen substituerte fenylalkyletylendiamin-platina(ii eller iv)-derivater og fenylalkyletylendiaminer
NO924064L (no) Nye i etylendelen substituerte fenylalkyletylendiamid-platina(ii eller iv)-derivater og fenylalkyletylendiaminer
IT8261969V0 (it) Fornello da campeggio e piu' in generale, trasportabile per usi analoghi.
ATE52031T1 (de) Plasmaproteinkonzentrate mit reduzierter thrombogenizitaet und deren verwendung in klinischer ersatztherapie.
ITFI920066A0 (it) Procedimento e attrezzatura per realizzare canali di condizionamento e simili mediante lastre piane autocoimbentri del detto tipo a sandwich.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee